Overview of 50 years' progress in upper gastrointestinal diseases.
There have been numerous and dramatic advances in our understanding of the mechanisms, causes and treatments of upper gastrointestinal diseases in the past 50 years. This review focuses on a few, not dealt with elsewhere in this special issue of the Journal. The early history of the recognition that nonsteroidal anti-inflammatory drugs are a major cause of peptic ulcer is described, with particular attention to the work of the pioneering Australian investigators. The story of the development of the histamine H(2)-receptor antagonists and the proton pump inhibitors is also outlined.
Yeomans
Neville D
ND
School of Medicine, University of Western Sydney, Penrith South DC, New South Wales, Australia. n.yeomans@uws.edu.au
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000266:history; D001315:Australia; D005762:Gastroenterology / Q000266:history* / Q000639:trends; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000266:history; D005765:Gastrointestinal Agents / Q000266:history* / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000266:history*; D006635:Histamine H2 Antagonists / Q000266:history; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D010437:Peptic Ulcer / Q000139:chemically induced / Q000266:history; D054328:Proton Pump Inhibitors / Q000266:history; D018570:Risk Assessment; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors